EGFR inhibitors square off at ASCO
Article Abstract:
The epidermal growth factor receptor (EGFR) inhibitors represent the first real market competition for the nascent targeted-cancer therapies and it provides a case study at the annual meeting of the American Society of Clinical Oncologists (ASCO) held on June 5-8, 2004. The antibody EGFR inhibitors target the extracellular portion of the receptor, whereas small molecule drugs tend to inhibit the intracellular tyrosine kinase domain.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
Article Abstract:
A method for imaging the inhibition of Hsp90 by 17-allylaminogeldanamycin (17-AAG) is developed and used to quantify as a function of time, the loss and recovery of HER2 induced by 17-AAG in animal tumors. This method allows noninvasive imaging of the pharmacodynamics of a targeted drug and also facilitates the rational design of combination therapy based on target inhibition.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Altruism and the economic on non-profit organisations. Making Sense of Non-Profit Organisations. The sustainable growth rate of non-profit organisations: the effect of efficiency, profitability and capital structure
- Abstracts: Factors explaining the inefficient valuation of intangibles. Intellectual capital and the capital market - organization and competence
- Abstracts: The changing attitude of European VCs. Next-generation monoclonals less profitable than trailblazers?
- Abstracts: Executive turnover in UK firms: the impact of Cadbury. What has the invisible hand achieved? A unified approach to the measurement of international accounting harmony
- Abstracts: Tests of the expectations hypothesis: resolving the anomalies when the short-term rate is the federal funds rate